News

/
/
Page 9
FDA Approves Eisai’s FYCOMPA® (perampanel) for Use as Monotherapy for the Treatment of Partial-Onset Seizures

   First antiepileptic drug (AED) to apply FDA’s regulatory pathway of extrapolation for monotherapy use; FDA proposed using this pathway to get monotherapy options to…

Do You Know a Junior Leader?

Our partners at the Tuberous Sclerosis Alliance are now offering their 3rd annual TS Alliance Junior Leader Program. If you are a young adult affected…

CNF 2017 Annual Educational Initiative: SUDEP

Each year, CNF selects a topic to be the focus of its child neurology community educational initiative. For 2017, CNF selected Sudden Unexplained Death in Epilepsy (SUDEP)…

Cerebral Palsy is a Diagnosis, Not a Destiny: NEW OFFERINGS

CCPM is on the Move Children’s Cerebral Palsy Movement (CCPM) executed a successful multi-institutional, multi-disciplinary scientific pilot study, involving boys & girls with CP that…

NEW INTERACTIVE GRAPHIC: Tools for Transitioning Young Adults with Neurologic Conditions

Led by CNF, the consensus statement, The Neurologist’s Role in Supporting Transition to Adult Health Care* was published in July 2016. The statement identifies 8 Common Principles for…

Midazolam Nasal Spray (USL261) Phase 3 Trial Meets Primary Efficacy Endpoint In Patients With Seizure Clusters

CAMBRIDGE, England, April 26, 2017 /PRNewswire/ — Proximagen Limited (Proximagen) today announced that its pivotal Phase 3 trial of intranasal midazolam (USL261) for the rescue treatment…

Exciting advancement for adolescents living with migraines!

FDA Approves Expanded Indication for Qudexy® XR (topiramate) Extended-Release Capsules to Include Prophylaxis of Migraine Headache in Adults and Adolescents Molecule Most Prescribed by Neurologists…

Rare Neurological Disease Special Report

Neurology Reviews presents its third annual Rare Neurological Disease Special Report, a compendium of articles and information covering a wide range of rare neurologic diseases. CNF…

Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC

MEDIA RELEASE • COMMUNIQUE AUX MEDIAS Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland https://www.novartis.com • MEDIENMITTEILUNG Novartis drug Votubia® receives EU approval to…

Creatine helps supply energy to all cells in the body. It helps increase adenosine triphosphate (ATP). Creatine is produced in the liver, which makes it…

February 1 is CCDS (Cerebral Creatine Deficiency Syndromes) Awareness Day

Learn important facts about creatine deficiencies by watching this video produced by the Association for Creatine Deficiencies (ACD, creatineinfo.org).  

Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC

Basel, January 31, 2017 – Novartis today announced that the European Commission has approved Votubia® (everolimus) dispersible tablets* as an adjunctive treatment for patients aged…

Special Needs Horseback Competition Provides Fun For Participants

The 121st Fort Worth Stock Show offers fun and entertainment for lots of fans. However for more than 200 horseback riders with special needs the…

Teacher Uses Puppetry and Filmmaking to Engage Students With Neurological Differences

Felt. Googly eyes. Socks. Pipe cleaners. Imagination. Sound familiar yet? Puppets! Patrick Waters, a teacher of special needs students, found that using these fun little…

Medikidz Explain Lennox-Gastaut Syndrome (LGS)

Eisai is pleased to announce the availability of the fifth comic book in the “Medikidz Explain Epilepsy” series, “Medikidz Explain Lennox-Gastaut Syndrome (LGS),” an educational comic…

CURE is now accepting LOIs for our first 2017 grant cycle.

NOW ACCEPTING APPLICATIONS CURE 2017 Cycle 1 Funding Opportunities CURE is now accepting LOIs for our first 2017 grant cycle. Innovator Award – $50,000 USD…

International Alliance for Pediatric Stroke (IAPS) News & World Stroke Day: October 29, 2016

Attention research teams: The NIH/NNHLBI recently announced a research project grant for perinatal stroke. This Funding Opportunity Announcement (FOA) solicits grant applications regarding basic or translational research…

GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

London, UK; 26 Sept 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: “GWP,” “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing…

Your Feedback Requested: Parents/Caregivers Medical Cannabis Survey

At the Child Neurology Foundation (CNF), our mission is to serve as a collaborative center of education and support for children living with neurologic conditions…

PCORI Annual Meeting Scholarships

The 2016 PCORI Annual Meeting is taking place in November in the greater Washington, D.C. area, and we’re offering scholarships to help patients, caregivers, and…

Start typing and press Enter to search

Shopping Cart